Last update 11 Mar 2026

Anti-CD3 x anti-HER2 bispecific antibody armed FPBMC(University of Virginia)

Overview

Basic Info

Drug Type
Cell therapy
Synonyms
Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Fresh Peripheral Blood Mononuclear Cells, HER2 FPBMC
Target
CD3 x HER2
Action
modulators
Mechanism
CD3 modulators(T cell surface glycoprotein CD3 modulators), HER2 modulators(Receptor tyrosine-protein kinase erbB-2 modulators)
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal DiseasesUrogenital Diseases
Active Indication
Metastatic breast cancerMetastatic castration-resistant prostate cancer
Inactive Indication-
Originator Organization
University of VirginiaUniversity of Virginia
Active Organization
University of VirginiaUniversity of Virginia
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Anti-CD3 x anti-HER2 bispecific antibody armed FPBMC(University of Virginia)
NCT07441889
/ Not yet recruitingPhase 1/2IIT
Phase I/II Study of Anti-CD3 x Anti-HER2 Bispecific Antibody (HER2Bi) Armed Fresh Peripheral Blood Mononuclear Cells (HER2 FPBMC) in Metastatic Castrate Resistant Prostate Cancer (mCRPC) and Metastatic Breast Cancer (MBC)
100 Clinical Results associated with Anti-CD3 x anti-HER2 bispecific antibody armed FPBMC(University of Virginia)
Login to view more data
100 Translational Medicine associated with Anti-CD3 x anti-HER2 bispecific antibody armed FPBMC(University of Virginia)
Login to view more data
100 Patents (Medical) associated with Anti-CD3 x anti-HER2 bispecific antibody armed FPBMC(University of Virginia)
Login to view more data
100 Deals associated with Anti-CD3 x anti-HER2 bispecific antibody armed FPBMC(University of Virginia)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic breast cancerPhase 2-
University of VirginiaUniversity of Virginia
01 Apr 2026
Metastatic castration-resistant prostate cancerPhase 2-
University of VirginiaUniversity of Virginia
01 Apr 2026
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free